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Although "many roads lead to atheroma ", the prevailing hypothesis at present is the Russell Ross' response-to-injury hypothesis, 
which sates that atherosclerosis is an inflammatory disease that involves several aspects of wound healing. It is noteworthy that, 
emphasized by the current studies of neurotrophic factors and nerve-immune cell interactions, neuroimmune mechanisms are 
increasingly implicated in the pathogenesis of a number of inflammatory diseases. Here we highlight the possibility that 
neuroimmune mechanisms, including the participation of neurotrophic factors and immune cells, may also be involved in the 
process of atherogenesis. Biomed Rev 1999; 10: 37-44. 
INTRODUCTION 
NGF's classical activity: a neuroeffector link 
Life at the neuronal level requires trophic support. Work initiated 
by the discovery of nerve growth factor (NGF) in the early 1950's 
and later embodied in the neurotrophic theory (1) has brought 
increasing insight into the bidirectional link between nerves 
and innervated effector (target) tissues (1-3). In auto-nomic 
nervous system, NGF-driven differentiation and survival of 
sympathetic and sensory neurons is well studied (1). NGF is a 
member of the neurotrophin family of proteins, including 
brain-derived neurotrophic factor (BDNF), neuro-trophin-3 
(NT-3), NT-4/5, NT-6, and NT-7 (3,4). Beginning with the original 
studies of Levi-Montalcini (1), it is known that the largest 
amount of NGF is secreted by the convoluted tubular cells of 
the male mouse submandibular gland. This organ contains NGF 
as an oligomeric macromolecule (7S) composed of alpha, beta 
and gamma subunits. The homodimer consisted of 
 
 
beta-subunits and with molecular weight of 26.5 kD is a nerve 
growth-promoting factor, namely, beta-NGF (2.5S NGF) (1), 
which further in the text will be referred to as NGF. The gamma-
NGF is a member of the kallikrein family of serine proteases, 
cleaving, for example, plasminogen into plasmin (5), a crucial 
factor for the conversion of latent transforming growth factor-
beta (TGF-J3) into active TGF-(3 (6), a key suppressor of 
atherogenesis (6,7). Biological actions of NGF are mediated by 
the initial ligation of two different cell surface receptors: (;') 
the low-affinity p75 NGF receptor (p75NGFR), also named 
p75 neurotrophin receptor, and («) the high-affinity receptor 
ty-rosine kinase (Trk), TrkA (3) (receptozyme). 
NGF's moonlighting: a neuroimmune link 
During some 25 years after its discovery, there have been few 
reasons given to indicate that NGF acts on noneuronal cells. 
Thus, in 1977, it was remarkable to discover that treatment of 
newborn rats with NGF caused a systemic increase in the num- 
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Table 1. Nerve growth factor and nonneuronal cells in 
atherogenesis 
Other cells 
   Endothelial cells* 
   Smooth muscle cells*  
  Fibroblasts  
   Platelets*  
   Adipocytes 
 
 
* These cells are also source of BDNF. Refs 8-21. 
ber of mast cells (MC) (8). Today, there is compelling evidence 
that NGF, in addition to its neurotrophic function, enhances 
survival and activity of a large number of nonneuronal cells, 
and is secreted not only by directly innervated cells but also 
by MC, lymphocytes and other cell types, implicated in the 
process of atherogenesis (Table 1). Also, atherogenic cytokines 
derived from immune cells increase NGF secretion in a variety 
of cells (18,22), whereas NGF induces release of various 
mediators from MC (23,24). Moreover, beyond their 
importance in differentiation and activation of immune cells, 
interleukin-6 (IL-6) and leukemia inhibitory factor (LIF) (25) 
and stem cell factor (SCF) (MC growth factor, c-kit ligand) (26) 
are able to enhance nerve growth. Indeed, there is at present 
considerable evidence that the sharing of ligands (growth 
factors, cytokines, and neurotransmitters) and their receptors 
constitute a molecular information network between neuronal, 
immune and effector (NIE) cells in different organs (25,27-
29), including blood vessels (30-32). Historically, 
RamonyCajal (cited in 33) and Hamburger and Levi-
Montalcini (34) firstly envisaged neuroimmune interactions 
and also neuronal programmed cell death (apoptosis) by their 
studies on the involvement of macrophages in neuronal injury 
and development. 
ATHEROGENESIS: HOT JUST FOR INTIMA 
The artery wall consists of intima, media, and adventitia, the 
latter gradually transits into periadventitial tissue, that is, the 
artery-associated adipose tissue (AAAT). An artery affected 
by atherosclerosis displays intimal and adventitial lesions 
associated with medial atrophy. 
Although "many roads lead to atheroma" (6) (Table 2), the 
prevailing hypothesis at present is the Russell Ross' response-
to-injury hypothesis, which sates that atherosclerosis is an 
inflammatory disease that involves several aspects of wound 
healing (35). The response-to-injury hypothesis proposes 
endothelial dysfunction, lymphocyte and monocyte 
extravasation into the intima, and vascular smooth muscle cell 
(VSMC) proliferation (35) and oversecretion of matrix molecules 














sclerotic plaques. Because advanced intimal lesions lead to 
luminal loss, resulting in infarction, the intima is considered by 
many authors the most important vascular area involved in 
atherogenesis (35,37-41). Recently, growing evidence, 
however, rises the possibility of alternative, adventitial (42,43) 
and AAAT (44,45) pathways of the vascular injury response, 
suggesting that atherogenesis is not just for intima. 
Our review will focus on possible role for the neurotrophins 
NGF and BDNF and the immune cells MC, macrophage and 
lymphocytes in neuroimmune mechanisms in atherosclerosis. 
NEUROTROPHINS, IMMUNE CELLS, AND ATHEROSCLERO- 
SIS 
 
Within the artery wall, VSMC comprise the primary target of 
the sympathetic neurons and, respectively, serve as the main 
source of NGF (17). Hence much of our insight into the 
possible role of NGF in atherogenesis arises from studies 
usually dealing with VSMC (46-50). Recent evidence shows that 
VSMC besides their classical role in providing neurotrophic 
support via secretion of NGF (17), BDNF and NT-3 (51) are also 
able to respond to these neurotrophins (49,52). Moreover, 
immune cells, like VSMC, secrete a plethora of mediators 
with neurotrophic, proinflammatory, fibrogenic and angiogenic 
effects that play an important role in tissue remodeling (9,23-
25,27,53-56). 
In vascular pathology, considerable evidence exists for the 
involvement of NGF and perivascular sympathetic innervation in 
hypertension (57,58). More recently, two publications deal 
with giant cell arteritis (31) and Kawasaki diseases (59). 
Indeed, an increasing body of evidence supports the hypothesis 
that the cell biology of atherosclerosis (35,39,43-45,60), including 
acute coronary syndromes (61,62), shares many similarities with 
inflammatory-fibroproliferative diseases (35,63,64), and also with 
cancer (65). It is noteworthy therefore that, emphasized by the 
current studies of NGF and immune cells (66,67) and nerve-
immune cell interactions (25,27-30,32), neuroimmune 
mechanisms are implicated in the pathogenesis of a large number 
of these diseases (68, their Table, this volume ofBiomedi-cal 
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also immune cells (6,35,53,60) that are potential sources of 
NGF (8-12) are identified in developing lesions of atherosclerosis, 
as well as an essential nonneuronal function of neurotro-phins 
implicated in cardiovascular tissue development (51,69), the role 
of neurotrophins in atherosclerosis has only recently emerged 
(45-50). Intriguingly, NGF shares a striking structural homology 
with proinsulin and exerts certain insulin-like effects on lipid 
metabolism in adipocytes (71,72) and both BDNF and NGF exert 
hypoglycemic effect acting on pancreatic beta cells, which also 
secrete NGF (73,74). Furthermore, atherogen-esis-associated 
growth factors, such as LIF, SCF, TGF-p, hepa-tocyte growth 
factor, vascular endothelial growth factor, and bone 
morphogenetic proteins (25,26,75-78) and even the 
paradigmic antherogenic factor platelet-derived growth factor 
(PDGF) (35) exert neurotrophic activities (79), and NGF uses 
similar intracellular signaling pathways as PDGF in VSMC (50). 
Given the key role of inflammation and fibrosis in the initiation 
and development of atherosclerotic lesions (35,37-40,43-45,60-
64), what role, for example, might NGF and MC play in the 
process of atherogenesis? First, NGF influences certain 
atherogenesis-associated functions of NIE cells including 
survival of peri vascular nerves (17), proliferation and activity of 
MC (8-10), and apoptosis and migration of VSMC (46,50,52). 
Second, atherogenesis related molecules, such as PDGF, IL-
1(3, and angiotensin II (47), and also thrombin (48) increase 
NGF secretion in cultured VSMC, whereas MC-derived mediators 
modulate the growth of VSMC (80). Third, local and/or 
systemic levels of NGF (68,81,82) and the number of MC 
(23,25,30,32,61,68) increase in response to inflammatory stimuli, 
and, importantly, exogenous administration of NGF inhibits 
such inflammatory reactions, whereas histamine receptor 
antagonists inhibit atherosclerotic intimal lesions (83). Fourth, 
there is an inverse relation between the density of peri vascular 
sympathetic nerves and the development of atherosclerosis 
(84). Finally, NGF upregulates low density lipoprotein receptor 
(LDLR)-related protein (85), a member of the LDLR gene family 
whose malfunction is causally related to atherosclerosis, while 
another neurotrophic factor, LIF, decreases serum cholesterol 
levels and upregulates LDLR, and thereby inhibits the 
development of atherosclerosis (86,87). Effects of NGF as 
potentially related to atherogenesis are summarized in Table 3. 
Altogether, these results taken in conjunction with the 
involvement of MC in LDL metabolism in atherosclerotic lesions 
(95) suggest a complex arrangement between lipoproteins, 
NGF, and immune cells and the process of atherogenesis. For 
example, in human coronary atherosclerosis, VSMC, like in 
culture conditions (49,52), express BDNF, NT-3, and NT-4/5, 
and their TrkB and TrkC receptors (52), while the level of NGF 
is significantly reduced and the adventitial p75NGFR immunore-
activity increased (70). Further, the number of MC (39,70) and 
lymphocyte aggregates (39), as well as their links to perivascu-lar 
nerves (96-98), is increased at the adventitia in atherosclerotic 
compared with control coronary.arteries. Most likely, the 
Table 3. NGF potentials in atherogenesis 
Promotion of survival of sympathetic neurons 
Stimulation of vascular smooth muscle cell migration 
Stimulation of vascular smooth muscle cell apoptosis 
Stimulation of mast cell proliferation 
Stimulation of release of mast cell mediators 
Stimulation of lymphocyte proliferation 
Stimulation of neutrophil apoptosis 
Stimulation of tissue repair 
Stimulation of angiogenesis 
Conversion of plasminogen to plasmin (gamma-NGF) 
Regulation of adipogenesis 
Increase in serum triglyceride and free fatty acid levels 
Upregulation of LDL receptor-related protein 
Upregulation of caveolin-1, -2 
Activation of antioxidant enzymes 
Activation of matrix metalloproteinase 
Inhibition of vascular permeability 
Inhibition of major histocompatibility class n expression 
Inhibition of synaptic norepinephrine release 
Refs 1,8,9,14,21,68,85,88-94. 
increased presence of these immonocytes, which are potential 
sources of NGF (9,11,29,70), is not able to compensate the 
neurotrophic deficit that may result from VSMC atrophy 
(17,99). This deficit may lead to degenerative changes in 
perivascular nerves (100-102). Nothworthy, (f) denervation 
results in a significant decrease in NGF content in vascular wall, 
particularly in the adventitia (102), and (if) apolipoprotein E-
deficient mice that spontaneously develop atherosclerosis (103) 
also develop neu-ronal degeneration (104). Clearly, the 
importance of neuroimmune and neuroeffector interactions in 
atherogenesis requires further evaluation. 
NGF: protective or damaging to the artery ? 
There are conflicting opinions about the role of NGF in 
atherogenesis. While some authors suggest that an elevated 
NGF amount may provide damaging effect (47), there are 
certain reasons to suggest that NGF might exert a 
vasculoprotectivc effect. First of all, brief myocardial ischemia 
induces a dysfunction of sympathetic cardiac innervation that is 
accompanied by a rapid increase in NGF release, whereas 
exogenous administration of NGF protects against such 
neuronal dysfunction, thus suggesting that the endogeneous 
NGF release is insufficient for complete neural protection (81). 
Second, as indicated in the Introduction, the process of 
atherogenesis involves several aspects of chronic inflammation 
and wound healing (35). It is noteworthy therefore that 
p75NGFR-deficient mice develop skin ulcers (105), while the 
administration of NGF promotes healing of skin (82,106) and 
corneal (107) ulcers, and inhibits experimental inflammation 
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cin and betamethasone (108). Significantly, patients with 
severe coronary atherosclerosis (7) and restenosis (6,7) do 
indeed have reduced levels of both active TGF-J3 and estrogen 
(7) and also mutation of type II TGF [3 receptor (67) 
compared to patients with normal coronary arteries, whereas 
one factor crucial for the activation of VSMC-secreted TGF-J3 
is plasmin (6) that can be generated upon the action of gamma-
NGF (5; also see 109,110 for NGF-TGF-(3- estrogen 
interactions). Future studies may provide the answer of 
whether TGF-(3-induced increase in NGF secretion by VSMC 
is damaging (47) or protective to the artery. Yet, the principle 
question remains: if NGF is causally related to atherogenesis, 
is it low or high levels of NGF that are associated with a 
possible vasculoprotective (atheroprotective) effect? 
Genetically-modified mice deficient in NGF or neurotrophin 
receptors (105,111) fed with high cholesterol diet may help to 
answer this question. Another pressing question is whether 
gamma-NGF (5) is expressed in atherosclerotic vascular wall? 
CONCLUSION AMD PERSPECTIVES 
From the evidence presented here the following main conclusion 
may be drawn: the neurotrophic theory and its currently 
expanded neuroimmune framework may be set into the context of 
neuroimmune hypothesis of atherosclerosis. Of course, many 
pressing questions remain to be answered, and future studies 
scheduled, in order to evaluate, for example, (i) plasma levels of 
NGF in patients with angina pectoris and with myocardial 
infarction, (ii) MC/basophils, lymphocytes, and platelets as 
potential peripheral markers for alterations in neurotrophins in 
atherosclerosis, and (Hi) potential involvement of AAAT in 
human atherosclerosis (44,45,112-120), as well as in Watanabe 
heritable hyperlipidemic rabbits and spontaneously hypertensive 
rats, and, more specifically, in neurotrophin-deficient mice and in 
MC-deficient mice (121) fed with cholesterol-supplemented 
diet. 
In effect, a continued pursuit of the possible interactive role of 
neurotrophic factors and immune cells in atherogenesis may 
help to answer many questions which have continuously arisen, 
and hence provide new insight into atherosclerosis. If the 
neuroimmune hypothesis of atherogenesis proposed herein is 
proved, a new, neurotrophin-directed (57; 122, this volume 
ofBiomedical Reviews) and immune cell-directed therapeutic 
approach in atherosclerosis may then be designed. Indeed, 
"the submerged areas of the NGF iceberg loom very large", 
Rita Levi-Montalcini stated in her Nobel prize lecture reviewing 
35 years of research on NGF (123). Blessedly, she is continuing 
to contribute. 
ACKNOWLEDGMENTS  
One of the authors (GNC) would like to thank his mother for 
giving him courage during her gentle improvement after a se- 
vere stroke. The authors thank Ms Jane Klickman for English 
editing, and Dr Yong Liang at Department of Neuroscience, 
Karolinska Institute, Stockholm, Sweden for critical reading 
the manuscript. 
REFERENCES 
1.   Levi-Montalcini R. The Saga of the Nerve Growth 
Factor. Preliminary Studies, Discovery, Further 
Development. World Scientific, Singapore, 1997. 
2.   Kahler CM, SchratzbergerP, WiedermannCJ. Response of 
vascular smooth muscle cells to the neuropeptide secre-
toneurin. A functional role for migration and proliferation in 
vitTO.ArteriosclerThromb VascBiol\991; 17:2029-2035. 
3.   Nagtegaal ID, Lakke EAJF, Marani E. Trophic and tropic 
factors in the development of the central nervous system. 
Arch PhysiolBiochem 1998; 106: 161-202. 
4.   Lai KO, Fu WY, Ip FCF, Ip NY. Cloning and expression of a 
novel neurotrophin, NT-7, from carp. Mol Cell Neurosci 
1998; 11:64-76. 
5.   OrestemNS.DvorakHF.BlanchatdMH, YoungM. Nerve 
growth factor: a protease that can activate plasminogen. 
ProcNatlAcadSciUSAl918; 75: 5497-5500. 
6.   Hayden MR, Reidy M. Many roads lead to atheroma. Nat 
Med 1995; 1:22-23. 
7.   Grainger DJ, Kemp PR, Metcalfe J, Liu AC, Lawn RM, 
Williams NRetal. The serum concentration of active 
transforming growth factor-p is severely depressed in 
advanced atherosclerosis. Nat Med 1995; 1:74-79. 
8.   Aloe L, Levi-Montalcini R. Mast cells increase in tissue of 
neonatal rats injected with nerve growth factor. Brain Res 
1977; 133:358-366. 
9.   LeonA, BurianiA, Dal TosoR, FabrisM, Romanello S, Aloe 
L, Levi-Montalcini R. Mast cells synthesize, store, and 
release nerve growth factor. ProcNatlAcadSci USA 1994; 
91:3739-3743. 
10. Burgi B, Otten UH, Ochensberger B, Rihs S, Heese K, 
Ehrhard PB et al. Basophil priming by neurotrophic factors. 
Activation through the trk receptor. JImmunol 1996; 157: 
5582-5588. 
11. LambiaseA, Bracci-LaudieroL, BoniniS,BoniniS,Starace 
G, D'Elios MM etal. Human CD4+ T cell clones produce and 
release nerve growth factor and express high-affinity nerve 
growth factor receptors. JAllergy Clin Immunol 1997; 100: 
408-414. 
12. Marcinkiewicz M, Marcinkiewicz J, Chen A, Leclaire F, 
Chretien M, Richardson P. Nerve growth factor and 
proprotein convertases furin and PC7 in transected sciatic 
nerves and in nerve segments cultured in conditioned 
media: their presence in Schwann cells, macrophages, and 
smoothmuscle cells. JComp Neural 1999; 403:471-485. 
13.Hannestad J, Levant! MB, Vega JA. Distribution of 







Biomed Rev 10, 1999 
Neuroimmune hypothesis of atherosclerosis 
  
nohistochemical study. / Neuroimmunol 1995; 58:  131-
137. 
14.Kannan Y, Usami K, Okada M, Shimizu S, Matsuda H. 
Nerve growth factor suppresses apoptosis of murine neu-
trophils. Biochem Biophys Res Commun 1992; 186: 1050-
1056. 
15. LabouyrieE, Dubus P, Groppi A, MahonFX,FerrerJ, Parrens M 
et al. Expression of neurotrophins and their receptors in 
human bonemaxrov/.AmJPathol 1999; 154:405-415. 
16. LeventhalC, RafiiS, RafiiD, ShaharA, Goldman SA. Endot-
helial trophic support of neuronal production and 
recruitment from the adult mammalian subependyma. Mol 
Cell Neuroscil999; 13:450-464. 
17. Cowen T, Gavazzi I. Plastisity in adult and ageing 
sympathetic neurons. ProgNeurobiol 1998; 54: 249-288. 
18. Hattori A, Iwasaki S, Murase K, Tsujimoto M, Sato M, 
Hay ashi K et al. Tumor necrosis factor is markedly synergis-tic 
with interleukin 1 andinterferon-gammainstimulatingthe 
production of nerve growth factor in fibroblasts. FEES Lett 
1994; 340:177-180. 
19. Yamamoto H, Gurney ME. Human platelets contain brain-
derived neurotrophic factor. JNeuroscil990; 10:3469-3478. 
20. Brusov OS, ZlobinaGP, NikolaevaEA, Ulas V, FaktorMI, 
Pavlova OA etal. The indices of the thrombocyte serotonin 
system and the nerve growth factor system in children with 
hereditary disorders of neuropsychic development. Zl 
Neurol Psikhiatr 1m SS Korsakova 1999; 98: 27-31 (in 
Russian). 
21. Nisoli E, Tonello C, Benarese M, Liberini P, Carruba MO. 
Expression of nerve growth factor in brown adipose tissue: 
implications for thermogenesis and obesity. 
Endocrinology'1996; 137:495-503. 
22. Brodie C. Platelet activating factor induces nerve growth 
factor production by rat asttocytes.NeurosciLett 1995; 186: 5-
8. 
23. ArtucM, HermesB, Steckelings UM, Grutzkan A, HenzBM. 
Mast cells and their mediators in cutaneous wound healing: 
Active participants or innocent bystanders. Exp Dermatol 
1999;8:1-16. 
24. Marshall JS, Gomi K, Blennerhassett MG, Bienenstock J. 
Nerve growth factor modulates the expression of 
inflammatory cytokines by mast cells via a prostanoid-
dependent mechanism. Jlmmunol 1999; 162:4271-4276. 
25. Marshall JS, Waserman S. Mast cells and the nerves -
potential interactions in the context of chronic disease. Clin 
Exp Allergy 1995;25:102-110. 
26. Carnahan JF, Patel DR, Miller JA. Stem cell factor is a 
neurotrophic factor for neural crest-derived chick sensory 
neurons. JNeurosci 1994; 14:1433-1440. 
27. McKay DM, Bienenstock J. The interaction between mast 
cells and nerves in the gastrointestinal tract. Immunol Today 
1994; 15: 533-53. 
28. Theodorou V, Fioramonti J, Bueno L. Intergrative neuro- 
immunology of the digestive gut tract. Vet Res 1996; 27:427-
442. 
29. Otten U, Gadient RA. Neurotrophins and cytokines - 
intermediaries between the immune and nervous systems. 
Int J DevNeurosci 1995; 13:147-151. 
30. Chaldakov GN, Ghenev PI, Vachanov K, Tonchev A, 
Pancheva R. Nerve-mast cell-nerve growth factor link: the 
mast cell as yin-yang modulator in inflammation and fibro-
sis. Biomed Revl995; 4:1-6. 
31. Saldanha G, Kongo J, Plant G, Acheson J, Levy I, Anand P. 
Decreased CGRP, but preserved Trk A immunoreacti vity in 
nerve fibers in inflamed human superficial temporal arteritis. 
JNeurolNeurosurg Psychiatry 1999; 66: 390-392. 
32. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, 
Theoharides TC. Morphological and functional demonstration 
of rat dura mater mast cell-neuron interactions in vitro andin 
vivo.BrainRes 1999; 849:1-15. 
33. Schreiber RC, Shadiack AM, Bennett TA, Sedwick CE, 
Zigmond RE. Changes in the macrophage population of the 
rat superior cervical ganglion after postganglionic nerve 
injury. JNeurobiol\995;27:141-153. 
34. Hamburger V,Levi-MontalciniR. Proliferation, 
differentiation and degeneration in the spinal ganglia of 
the chick embryo under normal and experimental 
conditions. J Exp Zoo/1949; 111:457-501. 
35. Ross R. Mechanisms of disease: Atherosclerosis - an 
inflammatory disease. NEnglJMedl999; 340: 115-126. 
36. Chaldakov GN, Vankov VN. Morphological aspects of 
secretion in the arterial smooth muscle cell, with special 
reference to the Golgi complex and microtubular 
cytoskeleton. Atherosclerosis 1986;61:175-192. 
37. Williams KJ, Tabas I. The response-to-retention hypothesis 
of early ath&mgen&sis.ArteriosclerThromb VascBiol 1995; 
15:551-561. 
38. Witztum JL. The oxidation hypothesis of atherosclerosis. 
Lancer 1994; 344:793-795. 
39. Wick G, Romen M, Amberger A, Metzler B, Mayr M, 
Falkensammer G et al. Atherosclerosis, autoimmunity, and 
vascular-associated lymphoid tissue. FASEB J 1997; 11: 
1199-1207. 
40. Libby P, Egan D, Skarlatos S. Roles of infectious agents in 
atherosclerosis and restenosis: an assessment of the 
evidence and need for future research. Circulation 1997; 
96: 4095-4103. 
41. Sloop GD. Insights into the relationship of fatty streaks to 
raised atherosclerotic lesions provided by the hemo-
rheologic-hemodynamic theory of atherogenesis. 
MedHypotheses 1998; 51: 385-388. 
42. Van der Loo B, Martin JF. The adventitia, endothelium and 
atherosclerosis. Int JMicrocirc Clin Exp 1997; 17:280-288. 
43. Kozai T, ShimokawaH, YamawakiT, Fukumoto Y, Kadokami T, 
Kuwata K et al. Platelet activating factor causes hyper-









Biomed Rev 10, 1999 
Chaldakov, Fiore, Stankulov, Triaca, Ghenev, and Aloe 
  
vitro.   Coron Artery Dis 1997; 8: 423-432. 
44. Arbustini E, Roberts WC. Morphological observations in 
the epicardial coronary arteries and their surroundings late 
after cardiac transplantation. AmJCardiol 1996; 78: 814-
820. 
45. Chaldakov GN, Properzi F, Ghenev PI, FioreM, Stankulov IS, 
Aloe L. Artery-associated adipose tissue and atherosclerosis: 
correlative analysis of NGF and mast cells in human 
coronary atherosclerosis [abstract]. Atherosclerosis 1999; 
146(Suppll):S33. 
46. Bono F, Lamarche I, Herbert JM. NGF exhibits a proapo-
ptotic activity for human vascular smooth muscle that is 
inhibited by TGF-P1.FEBS Lett 1997; 416:243-246. 
47. Creedon DJ, Tuttle JB. Synergistic increase in nerve growth 
factor secretion by cultured vascular smooth muscle cells 
treated with injury-related growth factors. JNeurosci Res 
1997; 47:277-286. 
48. ShererTB,Spitsbergen JM, Steers WD,TuttleJB. Thrombin 
regulates nerve growth factor secretion from vascular, but 
notbladdersmoothmusclecells. CellTissueRes 1997;289: 
155-161. 
49. Neomoto K, Fukamashi K, NemotoF, MiyataS, HamadaM, 
Nakamura Y et al. Gene expression of neurotrophins and 
their receptors in cultured rat vascular smooth muscle cells. 
BiochemBiophysResCommunl99&;245:284-288. 
50. Kraemer R, Nguyen H, March KL, Hempstad B. NGF 
activates similar inracellular signaling pathways in 
vascular smooth muscle cells as PDGF-BB but elicits 
different biological responses. ArteriosclerThromb VascBiol 
1999; 19: 1041-1050. 
51. Scarisbrick IA, Jones EG, Isackson PJ. Coexpression of 
mRNAs for NGF, BDNF, and NT-3 in the cardiovascular 
systemofthepre-andpostnatalrat.././Vewro.ya' 1993; 13:875-
893. 
52. Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, 
Tessarollo L, Mahadeo D etal. Neurotrophin and neurotropin 
receptors in vascular smooth muscle cells. Regulation of 
expressionin response toinjury.AmJPathol 1995; 147:309-
324. 
53. MiyamotoT, Sasaguri Y, SasaguriT, Azakami S, Yasukawa 
H, Kato Setal. Expression of stem cell factor in human aortic 
endothelial and smooth muscle cells. Atherosclerosis 1997; 
129:207-213. 
54. Patella V, Marino I, Arbustini E, Lamparter-Schummert B, 
Verga L, Adt M et al. Stem cell factor in mast cells and 
increased mast cell density in idiopathic and ischemic car-
diomyopathy. Circulation 1998;91:971-978. 
55. Qu Z, Huang X, Ahmadi P, Stenberg P, Liebler JM, Le AC et 
al. Synthesis of basic fibroblast growth factor by murine 
mast cells. Regulation by transforming growth factor-p, 
tumor necrosis factor-a, and stem cell factor. Int Arch 
Allergy Immunol 1998; 115:47-54. 
56. GrutzkauA, Kruger-Krasagakes S,BaumeisterH, SchwarzC, 
Kogel H, Welker P et al. Synthesis, storage, and release of 
vascular endothelial growth factor/vascular permeability 
factor (VEGF/VPF) by human mast cells: implications for the 
biological significance of VEGF206. MolBiol Cell 1998; 9: 
875-884. 
57. Rush RA, Mayo R, Zettler C. The regulation of nerve growth 
factor synthesis and delivery to peripheral neurons. 
P/irarmac77jerl995;65:93-123. 
58. Bell C. Neurotrophic abnormalities and development of high 
blood pressure in genetically hypertensive rats.BiomedRev 
1996; 6: 43-55. 
59. Falcini F, Cerinic MM, Ermini M, Generini S, Lomardi A, 
Pignone A et al. Nerve growth factor circulating levels are 
increased in Kawasaki disease: correlation with diseases 
activity and reduced angiotensin converting enzyme level. 
JRheumatoll996;23:1798-1802. 
60. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, S wedenborg J, 
Andersson U et al. Cytokine expression in advanced 
human atherosclerotic plaques: dominance of pro-
inflammatory (Thl)andmacrophage-
stimulatingcytokines.Af/!-erosclerosis 1999; 145:33-43. 
61. Kaartinen M, Van der Wal AC, Van der Loos CM, Piek JJ, 
Koch KT, Becker AE et al. Mast cell infiltration in acute 
coronary syndromes: implications for plaque rupture. J 
Am Coll Cardiol 1998; 32: 606-612. 
62. Lee WH, Lee Y, Kim JR, Chu JA, Lee SY, Jung JO et al. 
Activation of monocytes, T-lymphocytes and plasma 
inflammatory markers in angina patients. 
ExpMolMed\999', 31:159-164. 
63. Pasceri V, Yeh ETH. A tale of two diseases. Atherosclerosis 
andrheumatoid arthritis. Circulation 1999; 100:2124-2126. 
64. Chaldakov GN, Deyl Z, Vankov VN. Colchicine: possible 
new application of its antifibrotic (antisecretory) action. 
PhysiolBohemoslovl981;36:1-7. 
65. MarkowitzSD. Atherosclerosis, just another cancer? JClin 
Invest 1997; 100:2143-2145. 
66. Tuveri MA, Passiu G, Mathieu A, Aloe A. Nerve growth 
factor and mast cell distribution in the skin of patients with 
systemic sclerosis. ClinExp Rheumatol 1993; 11:319-322. 
67. Simone MD, De Santis S, Vigneti E, Papa G, Amadori S, Aloe L. 
Nerve growth factor: a survey of activity on immune and 
hematopoietic cells. HematolOncol 1999; 17:1-10. 
68. Aloe L, Micera A. Nerve growth factor: basic findings and 
clinical trials. BiomedRev 1999; 10:3-14. 
69. Donovan MJ, Hahn R, Tessarollo L, Hempstead BL. 
Identification of an essential nonneuronal function of NT-
3 in mammalian cardiac development. Nat Genet 1996; 
14:210-213. 
70. Chaldakov GN, Properzi F, Ghenev PI, Fiore M, Stankulov IS, 
Aloe L. Correlative analysis of NGF, p75NGF receptor and 
mast cells in human coronary atherosclerosis. An artery-to-
adipose tissue study, [abstract]. BiomedRev 1998; 9: VIII. 









Biomed Rev 10, 1999 
Neuroimmune hypothesis of atherosclerosis 
  
factor and its homologue proinsulin in intracellular hydrogen 
peroxide production and metabolism in adipocytes. Trans-
membrane signalling relative to insulin-mimicking effects. 
BiochemPharmacoll9B2; 31: 3163-3172. 
72. Ng TB, Wong CM. Epidermal and nerve growth factors 
manifest antilipolytic and lipogenic activities in isolated rat 
adipocytes. CompBiochemPhysiol(B) 1985; 81: 687-689. 
73.OnoMJchiharaJ,NonomuraT,ItakuraY,TaijiM,Nakayama C 
et al. Brain-derived neurotrophic factor reduces blood 
glucose level in obese diabetic mice but not in normal mice. 
BiochemBiophysResCommun 1997; 238:633-637. 
74. Rosenbaum T, Vidaltamayo R, Sanchez-Soto MC, Zentella 
A, Hiriart M. Pancreatic (3 cells synthesize and secrete nerve 
growth factor. ProcNatlAcadSci USA 1998; 95:7784-7788. 
75. BlottnerD, WolfN, LachmundA,Flanders KC, UnsickerK. 
TGF-fJ rescuses traget-deprived preganglionic sympathetic 
neurons in the spinal cord. EurJNeurosci 1996; 8:202-210. 
76. MainaF, Hilton MC, Anders R, Wyatt S, Klein R, Davies A. 
Multiple roles for hepatocyte growth factor in sympathetic 
neuron development.Neuron 1998; 20: 835-846. 
77. Sondell M, Lundborg G, Kanje M. Vascular endothelial 
growth factor has neurotrophic activity and stimulates 
axonal outgrowth, enhancing cell survival and Schwann cell 
proliferation in the peripheral nervous system. J Neurosci 
1999; 19:5731-5740. 
78. Schneider C, Wicht H, Enderich J, Wegner M, Rohrer H. 
Bone morphogenetic proteins are required in vivo for the 
generation of sympathetic neurons. Neuron 1999; 24: 861-
870. 
79. Eccleston PA, Funa K, Heldin CH. Expression of platelet-\    
derived growth factor (PDGF) and PDGF alpha- and beta-
receptors in the peripheral nervous system: an analysis of sciatic 
nerve and dorsal root ganglia. DevBiol 1993; 155:459-470. 
80. WangY,KovanenPT. Heparinproteogly cans released from 
rat serosal mast cells inhibit proliferation of rat aortic smooth 
muscle cells in culture. CircResl999; 84: 74-83. 
81. Abe T, Morgan DA, Gutterman DD. Protective role of nerve 
growth factor against postischemic dysfunction of 
sympathetic coronary innervation. Circulation 1997; 95: 213-
220. 
82. MatsudaH,KoyamaH,SatoH,SawadaJ,ItakuraA,Tanaka A 
et al. Role of nerve growth factor in cutaneous wound 
healing: accelerating effects in normal and healing-impaired 
diabeticmice. JExpMed 1998; 187: 297-306. 
83. MiyazawaN, Watanabe S, Matsuda A, Kondo K, Hashimoto H, 
Umemura Ketal. Role of histamine H1 and H2 receptor 
antagonists in the prevention of intimal thickening. Eur J 
Pharmacol 1998; 362:53-59. 
84. Kacem K, Bonvento G, SeylazJ. Effect of sympathectomy 
on the phenotype of smooth muscle cells of middle cerebral 
and ear arteries of hyperlipidemic rabbits. HistochemJ 1997; 
29: 279-286. 
85. Bu G, Sun Y, Schwartz AE, Holtzman DM. Nerve growth 
factor induces rapid increases in functional cell surface low 
densitylipoprotein-relatedprotein. JBiolChem 1998;273: 
13359-13365. 
86. Moran CS, Campbell JH, Campbell GR. Human leukemia 
inhibitory factor upregulates EDE receptors on liver cells 
and decreases serum cholesterol in the cholesterol-fed 
rabbit. ArteriosclerThrombVascBiol 1997; 17:1267-1273. 
87. Moran CS, Campbell JH, Simmons DE, Campbell GR. Human 
leukemia inhibitory factor inhibits development of 
experimental atherosclerosis. ArteriosclerThromb 1994; 
14:1356-1363. 
88. GalbiatiF,VolonteD,GilO,ZanazziG,SalzerJE,Sargiacomo 
M et al. Expression of caviolin-1 and -2 in differentiating 
PC12 cells and dorsal root ganglion neurons: caveolin-2 is 
up-regulated in response to cell injury. ProcNatlAcadSci 
USA\99%;95:10257-10262. 
89. Nonogaki K, Moser AH, ShigenagaJ, Feingold KR, Grunfeld C. 
Beta-nerve growth factor as a mediator of the acute phase 
response in vivo. BiochemBiophysResCommun 1996;219: 
956-961. 
90. Hermann JE, MenterDG, Hamada J, Marchetti D, Nakajima 
M, Nicolson GE. Mediation of NGF-stimulated extracellular 
matrix invasion by the human melanoma low-affinity p75 
neurotrophin receptor: melanoma p75 functions 
independently of trkA. MolBiol Cell 1993; 4: 1205-1216. 
91. Muir D. Metalloproteinase-dependent neurite outgrowth 
within a synthetic extracellular matrix is induced by nerve 
growthfactor. ExpCellRes 1994;210:243-252. 
92. Mills EM, Takeda K, Yu ZX, Ferrans V, Katagiri Y, Jiang H et 
al. Nerve growth factor treatment prevents the increase in 
superoxide produced by epidermal growth factor in PC 12 
cells. JBiolChem\99&;273:22165-22168. 
93. Neuman H, Misgeld T, Matsumuro K, Wekerle H. Neuro-
trophins inhibit major histocompatibility class II inducibi-
lity of microglia: involvement of the p75 neurotrophin recep-
tor.Neurobiologyl99&;95:5779-5784. 
94. Uey ama T, Hano T, Hamada M, Nishio I, Masuy ama Y. New 
role of nerve growth factor - an inhibitory neuromodulator 
of adrenergic transmission. BrainRes 1991; 559:293-296. 
95. Kovanen PT. Mast cells in human fatty streaks and athero-
mas: implications for intimal lipid accumulation. CurrOpin 
Lipidoll996;7:28l-2&6. 
96. Kohchi K, Takebayashi S, HirokiT, NobuyoshiM. 
Significance of adventitial inflammation of the coronary 
artery in patients with unstable angina: result at autopsy. 
Circulation \985\71:709-716. 
97. BaroldiG, SilverMD,MarianiF,GiulianoG. Correlation of 
morphological variables in the coronary atherosclerotic 
plaque with clinical patterns of ischemic heart disease. Am 
JCardiovascPathol 1988; 2: 159-172. 
98. Ghenev PI, Chaldakov GN. Neural-immune links in 
adventitial remodeling in human coronary atherosclerosis. 









Biomed Rev 10, 1999 
Chaldakov, Fiore, Stankulov, Triaca, Ghenev, and Aloe 
  
99.Seo HS, Lombard! DM, Polinsky P, Powell-Braxton L, 
Schwartz SM, Rosenfeld ME. Peripheral vascular stenosis 
in apolipoproteinE-deficientmice. Potential roles of lipid 
deposition, medial atrophy, and adventitial inflammation. 
ArteriosclerThrombVascBiol 1997; 17:3593-3601. 
100. Scott TM, Honey AC, Martin JF, Booth RF. Perivascular 
innervation is lost in experimental atherosclerosis. Car-
dioscience 1992; 3:145-153. 
101. Milner P, Crowe R, Loesch A, Anglin S, Burnstock G, 
McEwan JR. Neurocompenstory responses to balloon-
catheter-induced injury of the rat carotid artery. J Vase Res 
1997;34:31-40. 
102. LiuDT, ReidMT,BridgesDCMcL,RushRA.Denervation, 
but not decentralization, reduces nerve growth factor 
content of the mesenteric artery. J Neurochem 1996; 66: 
2295-2299. 
103. Rader DJ, Fitzgerald GA. State of the art: atherosclerosis in 
a limited edition. NatMed 1998; 4:899-900. 
104. Fullerton SM, Strittmatter WJ, Mathew WD. Peripheral 
sensory nerve defects in apolipoprotein E knockout mice. 
ExpNeuroll998; 153:156-163. 
105. Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV 
et al. Targeted mutation of the gene encoding the low 
affinity NGF receptor p75 leads to deficits in the peripheral 
sensory nervous system. Cell 1992; 69: 737-749. 
106. BernabeiR, LandiF, BoniniS, OnderG,LambiaseA, Pola 
Ret al. Effect of topical application of nerve growth factor 
on pressure ulcers. Lancet 1999; 354: 307. 
107. Lambiase A, Rama, P, Aloe L, Bonini S. Management of 
neuro trophic kerat op athy. CurrOpinOphtalmoll999', 10: 
270-277. 
108. Amico-Roxas M, Caruso A, Leone MG, Scifo R, Vanella A, 
Scapagnini U. Nerve growth factor inhibits some acute 
experimental inflammations. Arch IntPharmacodyn Ther 
1989;299:269-285. 
109. BCimSJ,ParkK,RudkinBB,DeyBR,SpornMB,RobertsAB. 
Nerve growth factor induces transcription of transforming 
growth factor-beta 1 through a specific promoter element 
inPC12cells./Bzo/C/zem 1994;269:3739-3744. 
110. Gollapudi L, Oblinger MM,. Estrogen and NGF synergis-
tically protect terminally differentiated, estrogen receptor-a-
transfected PC 12 cells from apoptosis. JNeurosci Res 
1999; 56: 471-478. 
111. Conover JC, Yancopoulos GD. Neurotrophin regulation 
of the developing nervous system: analyses of knockout 
mice. Rev Neurosci 1997; 8: 13-27. 
112. FunahashiT,NakamuraT,Shimomural,MaedaK, Kuriyama 
H.TakahashiMefa/. Roleofadipocytokinesonthepatho-
genesis of atherosclerosis in visceral obesity. Intern Med 
1999; 38:202-206. 
113. Friedman JM, Halaas JL. Leptin and the regulation of body 
weightin mammals. Nature 1998; 395:763-770. 
114. Gigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, 
Zemiman S et al. Expression of plasminogen activator 
inhibitor-1 in human adipose tissue: a role of tumornecro-
sisfactor-a.Atherosclerosis 1999; 143:81-90. 
115. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, 
Shaarma AM. Co-expression of renin-angiotensin system 
genes in human adipose tissue. JHypertens 1999; 17:555-
560. 
116. SamadF, Yamamoto K, Pandey M, LoskutoffDJ. Elevated 
expression of transforming growth factor-P in adipose 
tissue from obese mice. Mol Med 1997; 3: 37-48. 
117. IshiiT, AsuwaN, MasudaS, Ishikawa Y. The effects of a 
myocardial bridge on coronary atherosclerosis and 
ischemia./Par7zo/1998; 185:4-9. 
118. Ferrer P, Valentine M, Jenkins-West T, Gale T, Gu K, 
Havens C et al. Periadventitial changes in the balloon 
injured rat carotid artery, [abstract]. FASEBJ1996; 10: A618. 
119. Dettman RW, Denetclaw Jr W, Ordahl CP, Bristow J. 
Common epicardial origin of coronary vascular smooth 
muscle, perivascular fibroblasts, and intermyocardial fi-
broblasts in the avian heart. £>evBioll998\ 193: 169-181. 
120. Ichinose Y, Asoh H, Yano T, Yokoyama H, Inoue T, 
Tayama K et al. Use of a pericardial fat pad flap for 
preventing bronchopleural fistula: an experimental study 
focusing on the angiogenesis and cytokine production of 
the fat pad. Surg Today 1995;25: 811-815. 
121. GalliSJ,WershilBK. The two faces of the mast cell./Vafure 
1996:381:21-22. 
122. Furukawa S, Nitta A, Furukawa Y. Stimulation of neuro-
trophin synthesis by 4-methylcatechol: a promising 
approach for neuroprotection. BiomedRev 1999; 10:45-54. 
123. Levi-Montalcini R. The nerve growth factor 35 years later. 




















Biomed Rev 10, 1999 
